Purpose of review Co-infection with Plasmodium falciparum malaria and Epstein-Barr virus (EBV) are implicated in the cause of endemic Burkitt lymphoma (eBL), the most prevalent pediatric cancer in equatorial Africa. Although the causal association between EBV and eBL has been established, P. falciparum malaria's role is not as clearly defined. This review focuses on how malaria may disrupt EBV persistence and immunity.
Introduction
In recent years, meaningful decreases in malariaassociated morbidity and mortality have been observed worldwide because of multifactorial global efforts to control and prevent malaria [1] . These campaigns have significantly decreased malaria in endemic areas; however, it is far from being eradicated. Malaria vaccine efforts are underway with lofty goals of not only preventing disease but also ideally preventing infections and transmission. After considerable discussion about clinical endpoints for malaria vaccine efficacy trials, decreases in malaria-associated mortality and morbidity would be acceptable short-term until a vaccine is designed that prevents infection. Thus, the possibility exists that a vaccine (or other intervention) which prevents clinical malaria yet does not prevent infections might create a carrier state whereby children harbor untreated infections. One could argue that asymptomatic malaria infec-tions are beneficial and induce naturally acquired protective immunity [2] . Conversely, chronic malaria infections may have detrimental effects contributing to anemia [3] or malaria-associated diseases such as endemic Burkitt lymphoma (eBL) [4] . eBL has long been associated with early age Epstein-Barr virus (EBV) infection and geographically linked to holoendemic Plasmodium falciparum malaria [4, 5] . Several key observations have established a causal role for EBV in eBL tumorigenesis. EBV was first isolated from and subsequently found in nearly 100% of eBL tumors [6, 7] . EBV serosurveys concluded that children in developing countries experience their primary infection before the age of 3 years [8] . Also, significantly elevated antibody titers to EBV viral capsid antigen (VCA) were found in children who later went on to develop eBL [9] . Since these seminal observations, the role of EBV as a tumor virus and EBV-specific T-cell immune control has been extensively explored [10, 11] . In comparison, this review focuses on the role P. falciparum malaria plays in eBL pathogenesis.
There are two prevailing, though not mutually exclusive, theories to explain the relationship between EBV and P. falciparum malaria in eBL etiology [12] . One suggests that P. falciparum malaria induces polyclonal B-cell expansion and consequently lytic EBV reactivation, thus leading to the expansion of latently infected B cells and the likelihood of a c-myc translocation, which is a hallmark of all Burkitt lymphoma tumors. The other theory argues that EBV-specific T-cell immunity is selectively impaired during P. falciparum malaria coinfection, either as a cause or consequence of enhanced EBV replication, leading to loss of viral control. Our growing appreciation for the complexity of human immunity allows us to delve further into the question of how P. falciparum malaria contributes to EBV deregulation.
Epidemiologic studies to evaluate the role for Plasmodium falciparum malaria in endemic Burkitt lymphoma Whereas the causal association between EBV and eBL has been established, P. falciparum malaria's role in eBL pathogenesis is not as well understood. Holoendemic malaria is characterized by intense perennial transmission with the highest morbidity and mortality in children under the age of 5 years. Under such conditions, infants and young children are repeatedly infected with P. falciparum malaria, and can harbor chronic, asymptomatic, often untreated infections. Recurrent infections engender partial immunity to P. falciparum malaria which allows sustained often high-density infections [2]. As both chronic and acute P. falciparum malaria infections are common in children residing in holoendemic areas, deconvoluting the multiple opportunities malaria has to influence EBV persistence is challenging.
Antimalarial treatment in holoendemic areas has been associated with a decrease in eBL incidence [13, 14] , although few studies have directly addressed the causality. A historical 'malaria-suppression' trial was conducted in Tanzania from 1977 to 1982 in an area monitoring eBL and malaria prevalence [15] . This intervention study distributed chloroquine to approximately 100 000 children below 10 years of age every 2 weeks for 5 years in an explicit attempt to reduce eBL incidence. They observed a decrease in eBL, but could not conclude that treating malaria was the sole mediator because eBL incidence had been declining prior to the study. However, the prevalence of malaria cases also declined prior to the intervention mirroring the decline in eBL incidence.
Other attempts to determine if relative peaks in malaria act as a 'trigger' of eBL by analyzing space-time clustering or seasonality of cases were also inconclusive [16] . However, using spatial analytical models, significant high-risk clusters for eBL incidence were found within a malaria holoendemic region, thereby highlighting the heterogeneity of individual malaria exposure within holoendemic areas [17] . In addition, though the incidence of eBL is significantly lower in areas with hypoendemic malaria, eBL may still occur [18, 19] . These observations support the premise that timing of co-infection and duration of P. falciparum malaria infections on an individual level is critical for understanding the dysregulation of EBV leading to eBL.
The coincidence of P. falciparum malaria infection preceding eBL further supports a temporal interaction with EBV. The average age of eBL patients in malarious areas was noted to be 8.1 years, whereas in low-risk malarious areas it was 16.2 years [20] . In addition, immigrants from malaria hypoendemic areas who moved to holoendemic areas presented with eBL in late adolescents and adulthood [20] . A similar pattern was also found in another study where most adult cases of eBL were born in hypoendemic areas [21] . Figure 1 depicts the chronology of EBV and P. falciparum malaria co-infections in relation to eBL incidence in malaria holoendemic areas. The peak age-related incidence of eBL is 4-9 years of age [19, 20] , after the age at which P. falciparum malaria-associated morbidity, mortality, and parasite densities are the highest. Even though these children experience their primary EBV infection before 3 years of life [8] it is extremely rare for a child to develop eBL before 2 years of age, suggesting a prolonged interaction is necessary for these co-infections to promote tumorigenesis. In support of this, the Tanzanian study [15] reported a 2-year lag between P. falciparum malaria burden and eBL incidence, with a concomitant increase in eBL incidence after the intervention was stopped. Burkitt lymphoma is one of the most rapidly dividing human tumors [10], thus the eBL 'triggering event' must occur proximal to tumorigenesis. Malaria and EBV co-infections are common in 436 Tropical and travel-associated diseases
Key points
Acute and chronic Plasmodium falciparum malaria infections may differentially impact T-cell immunity to EBV latent and lytic antigens. A systems biology approach simultaneously measuring T-cell immune control over EBV latency and lytic reactivation during acute and chronic P. falciparum malaria infections will improve our understanding of eBL etiology. An improved understanding of the sequence of events during P. falciparum malaria and EBV coinfections will help target eBL prevention strategies.
children residing in high-risk eBL areas, although the incidence of eBL is only 1-5 per 100 000 children annually. P. falciparum malaria may play multiple roles in eBL pathogenesis whereby co-infection during primary EBV infection sets the stage for deregulation of EBV latency, and repeated malaria infection exacerbates EBV homeostasis and T-cell immunity.
Epstein-Barr virus-specific T-cell immune deregulation by Plasmodium falciparum malaria
On the basis of other studies of acute infectious mononucleosis and healthy EBV seropositive adults, we know that EBV-specific T cells restrict viral replication and limit the number of latently infected B cells [22] . Thus, EBV load in peripheral blood has been used as surrogate measure for loss of T-cell-mediated viral control [23 ] .
The first study to measure EBV load in children living in a malaria holoendemic area found that the youngest children had significantly higher EBV loads compared to older children, adults, and children from a hypoendemic area [24] . Ensuing studies measured EBV before and after episodes of acute clinical malaria infection, and even though viremia was consistently higher in acute cases than controls, changes in viral load resulting from an episode of acute P. falciparum malaria could not be consistently measured after the episode resolved [24] [25] [26] [27] [28] . These contradictory findings could be the results of differences in cumulative P. falciparum malaria exposure and the frequency of latently infected B cells present. A recent study using multilevel mixed modeling found that children residing in a malaria holoendemic area experienced their primary EBV infection signifi-cantly earlier compared to children from a hypoendemic area and that individual malaria burdens over time were significant predictors of higher EBV viral load (Rochford, unpublished observation). These findings highlight the need for prospective studies designed to measure individual-level exposure to both P. falciparum malaria and EBV in order to understand how the heterogeneity in timing and intensity of these co-infections interact.
In immune-competent individuals, EBV persistence is an elegant balance between viral immune evasion strategies and regulation mediated by CD8 þ and CD4 þ T cells specific to a hierarchy of latent and lytic EBV antigens [23 ,29] . The notion that P. falciparum malaria interferes with immunological control over EBV occurred early on [30] , even before studies directly assessing the impact of malaria on EBV-specific T-cell function were conducted. These seminal studies measured in-vitro regression of EBV-induced B-cell transformation and concluded that acute P. falciparum malaria infection and chronic P. falciparum malaria exposure resulted in a loss of EBVspecific T-cell immunity [31] [32] [33] . This assay measured T-cell immunity against latent, but not lytic cycle antigens [34] , and was not compared to T-cell responses to P. falciparum malaria antigens or other measurements of global immune competence.
A more recent study measured EBV specificity and function by interferon (IFN)-g enzyme-linked immunospot (ELISPOT), concluding that children 5-9 years of age, after recurrent P. falciparum malaria infections, had impaired response to both lytic and latent EBV CD8 þ T-cell epitope peptides compared to children from a hypoendemic area [35] . A transient impairment of IFN-g ELISPOT recall responses around an episode of acute P. falciparum malaria was consistent with earlier regression studies. However, the decrease in T-cell immunity did not accompany a concomitant increase in EBV load, although viremia remained significantly higher in P. falciparum malaria cases compared to healthy controls even though T-cell responses were restored to normal levels [26] . It is possible that this loss of EBVspecific T cells in the peripheral circulation was because of T-cell trafficking to the site of EBV replication during acute infection. A third study examined the duration of IFN-g ELISPOT recall responses over a 2-year period using both an ecologic and individual-level definition for P. falciparum malaria exposure, and found that T-cell responses gradually diminished to EBV lytic but not latent antigens in 5-9-year-old malaria-exposed children compared to other age groups and nonmalaria-exposed children (Snider, Moormann, unpublished observation).
In contrast, IFN-g recall responses to EBV lytic and latent antigens in children diagnosed with eBL were robust; however, the effector cell secreting IFN-g cannot be identified by ELISPOT [36] . Table 1 summarizes the Timing of co-infections prior to peak age-related incidence of endemic Burkitt lymphoma (eBL) suggests a cumulative interaction that results in the deterioration of immune control over Epstein-Barr virus (EBV). Pf, Plasmodium falciparuum. and hypoendemic (n ¼ 60) malaria-exposed children to children with eBL (n ¼ 44) First study to directly measure EBV-specific T-cell immunity in children diagnosed with eBL and discovered that eBL children were deficient in IFN-g ELISPOT responses to EBNA1 (the sole EBV antigen expressed by eBL tumor cells) but not EBV lytic and latent CD8-epitope peptides.
eBL patients had IgG1 subclass antibodies to EBNA1, similar to control groups, suggesting loss of EBNA1-specific Th1-polarized T cells.
Lack of IFN-g ELISPOT to EBNA1 was associated with higher EBV load.
Snider and Moormann (unpublished observation)
Repeated cross-sectional study from same children over 2-year period.
Compared holoendemic (n ¼ 66) and hypoendemic (n ¼ 83) malaria-exposed children over time Using both a geographic and individual-level definition of malaria exposure, found a gradual decrease in EBV lytic antigen CD8þ T-cell response but not latent antigen responses measured by IFN-g ELISPOT.
Children 5-9 years of age had significantly diminished CD8þ T-cell IFN-g responses to EBV lytic but not latent antigens associated with malaria exposure compared to other age and malaria exposure groups.
eBL, endemic Burkitt lymphoma; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; ELISPOT, enzyme-linked immunospot; IFN, interferon; Pf, Plasmodium falciparum.
relevant studies directly investigating the impact of P. falciparum malaria on immunity to EBV.
Advancements in polychromatic flow cytometry have enabled us to learn more about human T-cell differentiation and function [37] and EBV-specific T-cell phenotypes, especially when blood sample volumes are limited. Using a 16-parameter flow cytometry panel developed to quantify differentiation, exhaustion, senescence, and homeostatic potential for EBV-specific CD8 þ T-cell restricted by HLA AÃ0201 to epitopes derived from latently expressed and lytic phase proteins, we found that individuals residing in a malaria holoendemic area have significantly more differentiated EBV-specific CD8 þ T cells compared to those residing in a hypoendemic area, and this profile shift was strongest for responses to EBV latent antigens (Moormann, Price, Chattopadhyay, unpublished observation). Taken together, these studies suggest that P. falciparum malaria co-infections during the establishment of EBV-latency may negatively impact EBV latent antigen-specific Tcell lineage commitment and that recurrent P. falciparum malaria infections over time diminish the functional capacity of EBV lytic antigen-specific T-cells.
Malaria's influence on B cells (wherein Epstein-Barr virus latently resides)
The development of humoral immunity is important for mediating protection against P. falciparum malaria, yet identifying which antibodies confer protection given the plethora of immunogenic parasite antigens remains enigmatic [2] . Seroprevalence to malaria antigens by the age at which a child is at risk for eBL reflects cumulative lifetime exposure and could be used to infer differences in transmission intensity when comparing populations. The caveat to applying single P. falciparum malarial antibody titers as a surrogate for the number or severity of past P. falciparum malaria infections is they are not quantitative and depend on the immunogenicity of the malaria antigen and the longevity of the antibody response being measured [38 ,39,40] .
Antibodies also play a role in limiting EBV infection and reflect the clinical status of the individual [41] . During primary EBV infection, immunoglobulin (Ig)M to VCA appears first, followed by VCA IgG that persists through life. Epstein-Barr nuclear antigen (EBNA1) IgG is detectable at 2-4 months after infection and remains throughout life. The Z transactivation antigen (ZEBRA or Zta) is an immediate early protein indicative of EBV replication and signifies the switch from latent to lytic replication [42 ] . Elevated VCA IgG antibody levels have been associated with eBL incidence [9] . A recent study found elevated anti-ZEBRA and anti-VCA levels in eBL patients compared with healthy children, and elevated ZEBRA antibodies were associated with higher EBV load in eBL children [43 ] . However, there is no consensus on the cumulative effect of P. falciparum malaria on EBV antibody titers in otherwise healthy children. A number of early studies on acute P. falciparum malaria found no difference in anti-VCA titers during and after P. falciparum malaria infection or among residents of different malaria transmission areas [44, 45] . Another study on acute P. falciparum malaria reported that ZEBRA IgG levels were significantly higher among children infected with P. falciparum malaria compared with controls [25] . The only study to examine the effect of chronic P. falciparum malaria on EBV antibody titers found higher IgG titers to EBNA1, VCA, and ZEBRA in children from a malaria holoendemic area compared to children from a hypoendemic area [46] . Meanwhile, a significant decrease in IgG titers for all EBV antigens with increasing age was observed in children from the hypoendemic area [46] . These observations suggest that antibody titers may be useful to monitor cumulative EBV latency and lytic reactivation but are not supple enough to directly measure the influence of P. falciparum malaria on EBVinfected B cells.
P. falciparum malaria has been shown to be a powerful B-cell mitogen inducing hypergamma-globulinemia [47] [48] [49] . The cysteine-rich interdomain region 1a (CIDR1a) domain of the P. falciparum erythrocyte membrane protein 1 (P. falciparumEMP1) has been shown in vitro to activate proliferation of B cells from individuals with no previous malaria exposure, preferentially targeting the activation of memory B cells, and providing protection against apoptosis [50] . A direct link between CIDR1a and EBV-infected B cells has also been demonstrated, suggesting CIDR1a could trigger reactivation of EBV during P. falciparum malaria infection [51] . Directly testing this interaction in vivo presents the obvious limitation for human studies, nonetheless the possibility remains that chronic P. falciparum malaria stimulation could continue to reactivate latently infected B cells even in the absence of acute malaria infections.
More recent attention has focused on the generation of human B-cell memory subsets and deciphering signals that determine if antibodies are secreted from long-lived or short-lived plasma cells [52] [53] [54] . As an immune evasion strategy, malaria appears to directly influence B-cell differentiation by impeding the development of longlived memory B cells and allowing the generation of atypical short-lived memory B cells [55 ,56] . Considering that B cells are where EBV persists, integrating the influence of EBV on the B-cell compartment with signals from P. falciparum malaria poses choreographic challenges [57 ] . Flow cytometry allows the delineation of naïve B cells into memory subsets. CD10 is a classical marker for germinal center B cells and eBL tumor cells [10] . However, CD10 is also expressed on immature transitional B cells present during chronic infection [58] . In healthy EBV seropositive individuals, EBV is strictly cell-associated and found in the memory B-cell compartment [10] . Children with acute clinical malaria are found to have a significantly higher number of transitional B cells in their peripheral circulation [59] ; and this subset is more susceptible to EBV infection compared to other memory B-cell subsets and also expresses elevated levels of microRNA which is important in blocking B-cell differentiation [60 ] . Malaria-induced alterations in B-cell differentiation in conjunction with identifying possible alternative EBV reservoirs has yet to be fully investigated.
Conclusion
There is still much to learn about the host orchestration of recurrent P. falciparum malaria infections and EBV persistence that crescendo into eBL. Unexplored moderators of immunity include innate immune signals, other lymphocyte subsets such as natural killer cells, gammadelta T cells, and regulatory T cells. Exploring human genetic susceptibility for eBL necessitates large DNA repositories linked with medical informatics that may shed new light on causative pathways. Designing studies using a systems biology approach will allow us to encompass the complexity and diversity of human immune responses to infectious diseases whereby our understanding of eBL pathogenesis will achieve a new zenith.
